-
Mashup Score: 1Individualized Approaches and Challenges in Myelofibrosis - 7 day(s) ago
Raajit K. Rampal, MD, PhD, discusses how the field of gene therapy and precision medicine is evolving in the context of myelofibrosis treatment.
Source: www.targetedonc.comCategories: General Medicine News, Onc News and JournalsTweet
-
Mashup Score: 1Future Management and Unmet Needs in Myelofibrosis - 14 day(s) ago
Dr. Bose shares his vision for the future management of patients with intermediate myelofibrosis, including the unmet needs with current treatment options and the emerging data he is closely following.
Source: www.targetedonc.comCategories: General Medicine News, Onc News and JournalsTweet
-
Mashup Score: 0
Dr. Bose discusses when he typically initiates ruxolitinib for his intermediate- or high-risk myelofibrosis patients.
Source: www.targetedonc.comCategories: General Medicine News, Onc News and JournalsTweet
-
Mashup Score: 0Factors Considered for Initial Therapy in Myelofibrosis - 20 day(s) ago
Dr. Bose shares his perspective on the factors he considers when deciding on initial therapy for myelofibrosis, including his approach to timing of treatment initiation and how splenomegaly influences his choice of JAK inhibitors.
Source: www.targetedonc.comCategories: General Medicine News, Onc News and JournalsTweet
-
Mashup Score: 0How the PERSIST-2 Results Show The Benefit of Pacritinib in MF - 23 day(s) ago
During a Case-Based Roundtable® event, John Mascarenhas, MD, discussed the efficacy data behind the use of pacritinib in patients with myelofibrosis in the first article of a 2-part series.
Source: www.targetedonc.comCategories: General Medicine News, Onc News and JournalsTweet
-
Mashup Score: 1Savona Discusses First-Line JAK Inhibition for Patients With Myelofibrosis at Risk of Anemia - 29 day(s) ago
During a Case-Based Roundtable® event, Michael Savona, MD, and participants discussed the case of a patient with myelofibrosis and moderate anemia receiving JAK inhibitor therapy.
Source: www.targetedonc.comCategories: General Medicine News, Onc News and JournalsTweet
-
Mashup Score: 0Perspectives on the Future on Myelofibrosis Treatment - 1 month(s) ago
Stephen T. Oh, MD, PhD, concludes with thoughts on the future treatment landscape for myelofibrosis.
Source: www.targetedonc.comCategories: General Medicine News, Onc News and JournalsTweet
-
Mashup Score: 0Patient Profile: A 63-Year-Old Man with Myelofibrosis - 2 month(s) ago
Stephen T. Oh, MD, PhD, presents the case of a 63-year-old man previously diagnosed and treated with primary myelofibrosis.
Source: www.targetedonc.comCategories: General Medicine News, Onc News and JournalsTweet
-
Mashup Score: 1Targeted Approaches in Myelofibrosis Treatment - 2 month(s) ago
Raajit K. Rampal, MD, PhD, discusses some of the promising emerging therapies for myelofibrosis that target different pathways at the Fifth Annual Miami Cancer Institute Global Summit on Immunotherapies for Hematologic Malignancies, hosted by Dr. Guenther Koehne and Miami Cancer Institute.
Source: www.targetedonc.comCategories: General Medicine News, Onc News and JournalsTweet
-
Mashup Score: 1
Haifa Kathrin Al-Ali, MD, discussed findings from the phase 1/2 CA011-023 study of BMS-986158 combined with ruxolitinib or fedratinib in myelofibrosis.
Source: www.targetedonc.comCategories: General Medicine News, Onc News and JournalsTweet
WATCH: @RaajitRampal discusses how the field of gene therapy and precision medicine is evolving in the context of #myelofibrosis treatment. #MPNSM | @MSKCancerCenter https://t.co/cGMndHxNtk